Articles tagged with Prostate Cancer
A six-gene signature has been identified that can predict survival in men with aggressive prostate cancer. The test uses blood samples and shows promise for determining the course of action for patients, clinical trial eligibility, and targeted studies.
Researchers discovered a new function of PARP-1 that regulates both DNA damage repair and androgen receptor activity, suggesting that inhibiting this enzyme could slow prostate cancer growth. This finding provides a new approach to treating advanced prostate cancer, which currently has limited treatment options.
Researchers identified genetic signatures that can predict the progression of castration-resistant prostate cancer, with patients having the signature living an average of 9.2 months compared to 21.6 months without the signature. These findings hold promise for improving patient outcomes and enabling better clinical trials.
Researchers have designed a blood test that can detect aggressive prostate cancers by analyzing the pattern of gene activity in blood cells. The test, which reads genetic changes like a barcode, can accurately identify patients with advanced prostate cancers and predict their survival time.
Researchers create precision blood test that uses gene patterns in blood cells to identify advanced-stage prostate cancer patients with worst prognosis. The test can be used to select those in need of immediate treatment.
Researchers found that common polymorphisms in the T2R38 gene were correlated with the incidence of bacterial sinus infections, demonstrating a genetic link to individual differences in respiratory infection susceptibility. In companion pieces, studies on PSD-95 expression and progranulin deficiency shed light on potential therapeutic ...
Emanuel Hamelburg, a Boston-area prostate cancer survivor, has been recognized for his dedication to cancer awareness and advocacy. He was awarded the Survivor Circle Award by the American Society for Radiation Oncology (ASTRO) in 2012.
Prostate cancer cases expected to reach nearly 242,000 diagnoses in 2012. New guidelines introduce active surveillance as a viable alternative to immediate treatment for low-risk tumors.
A study has identified 12 genetic markers associated with erectile dysfunction in prostate cancer patients treated with radiation. The findings may help clinicians predict complications and develop therapies to alleviate side effects.
Researchers at Thomas Jefferson University found that contrast-enhanced ultrasound detected higher-grade prostate cancers in 55% of patients, compared to 17% with conventional biopsy methods. The technique uses microbubbles to measure changes in blood flow and requires fewer needle biopsies.
A recent study by Mayo Clinic researchers found that men with high levels of 'cancer-specific anxiety' after prostate cancer surgery are more likely to experience low sexual satisfaction and depression. Counseling may be beneficial in addressing these concerns and improving quality of life for these patients.
A new research model estimates that men with low-risk prostate cancer who choose active surveillance may live 6.4 years without treatment, while those who undergo immediate radical prostatectomy may gain an average of 1.8 months of additional life.
A new study in The Journal of Urology presents promising results on the use of MRI to assess eligibility for active surveillance in men with clinically low risk prostate cancer. The findings suggest that clear tumor visualization on MRI is predictive of disease status upgrades on confirmatory biopsy, highlighting the potential of MRI t...
Research finds that obesity promotes prostate cancer growth by changing gene expression in fat surrounding the prostate, increasing risk of aggressive disease. The study suggests a personalized approach to lifestyle and therapeutic strategies for overweight men with prostate cancer.
A recent study has confirmed that an association between XMRV and prostate cancer was due to laboratory contamination. The researchers found that the virus was introduced into prostate tissue samples through contact with a different cell line, which had been contaminated with XMRV in the 1990s.
A phase 3 trial confirms abiraterone acetate's efficacy in extending average survival time to 15.8 months for castration-resistant prostate cancer patients. The treatment, which blocks testosterone production, also has a good safety profile.
Hartzband and Groopman argue that expert recommendations often ignore vital dimensions of life and are based on flawed calculations. They propose a new approach for individual patients to weigh risk and benefit, and emphasize the importance of nuanced judgment in medical decisions.
Researchers found that fusion-negative prostate cancers have different DNA methylation patterns than healthy cells, with increased EZH2 enzyme activity. This discovery may lead to more specific treatments and improved diagnosis for prostate cancer patients.
Researchers will investigate how sulforaphane in broccoli affects prostate tissue gene expression and metabolism in men at risk of developing prostate cancer. The study aims to provide evidence that diets rich in cruciferous vegetables or sulforaphane can reduce the likelihood of metastatic cancer.
A study published in Archives of Neurology found an association between Parkinson disease and an increased risk of prostate cancer and melanoma in patients with PD and their relatives. The research used a Utah genealogic database and a statewide cancer registry to examine the relationship between the two diseases.
A study published in Cancer Epidemiology, Biomarkers & Prevention establishes the association of IL-16 with prostate cancer in men of both African and European descent. Researchers found new polymorphisms in the gene unique to African Americans that confer risk, providing a potential biomarker for prostate cancer.
Researchers at Washington State University have identified a biological mechanism connecting trichomoniasis, a curable sexually transmitted disease, to an increased risk of developing prostate cancer in men. The study reveals that the parasite activates a series of proteins, with one protein acting as a key regulator in this process.
A multicenter study found that taking aspirin is associated with a lower risk of death from prostate cancer, especially in high-risk disease. The study analyzed data from almost 6,000 men with prostate cancer treated with surgery or radiotherapy, and the results showed a significant reduction in mortality rates and cancer recurrence.
Researchers found that tamoxifen effectively suppresses gynecomastia and breast pain in men with prostate cancer. Treatment with tamoxifen was more successful than with aromatase inhibitors or radiotherapy in reducing breast symptoms.
A new study published in The Journal of Urology reports that PSA testing has led to improved survival rates for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body. The disparity between African American and Caucasian men has been resolved, with African American men now having a compara...
A study led by Vanderbilt-Ingram Cancer Center finds that black men with prostate cancer receive lower quality surgical care than white men. Black men are less likely to use high-volume surgeons and hospitals, resulting in longer hospital stays and higher mortality rates.
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
A recent study published in Carcinogenesis found that cooking red meats at high temperatures, especially pan-frying, increases the risk of advanced prostate cancer. Men who consumed more than two servings of red meat cooked at high temperatures were 40% more likely to develop advanced prostate cancer.
Researchers developed a new prostate cancer screening method that combines drug therapy with changes in PSA levels to identify men with high-risk prostate cancer. The study showed that using PSA with these drugs can help differentiate between prostate cancer and benign disease, even in patients with difficult diagnoses.
Researchers reviewed clinical trials on calcium and vitamin D supplements for men with prostate cancer undergoing hormone therapy, finding that these supplements did not prevent bone loss. The study suggests that these supplements may actually increase the risk of cardiovascular disease and aggressive prostate cancer.
Researchers found two opposing proteins regulating the same set of genes in prostate cancer, suggesting potential therapeutic targets. The study identified genetic markers associated with tumor relapse, which could help predict patient outcomes.
A new study found that over half of malignant prostate cancers have both high-risk HPV 18 and EBV, with HPV alone present in 70% of the cancers. The research suggests a potential collaboration between the two viruses to promote cancer cell survival.
The study suggests that eliminating the PSA test would result in more men being diagnosed with metastatic prostate cancer, leading to higher mortality rates. Prostate cancer death rates have been reduced by nearly 40% over the past 20 years, largely due to early detection through PSA testing.
The study found that without PSA testing, approximately 25,000 cases of advanced prostate cancer would occur in 2008, three times the actual number observed. This would result in more men experiencing aggressive disease with limited treatment options.
A new study from Harvard School of Public Health found that men with prostate cancer are more likely to die from preventable conditions such as heart disease than the disease itself. The study emphasizes the importance of healthy lifestyle changes in prostate cancer management.
Researchers found that paxillin regulates cell growth even in hormone therapy-resistant tumors, providing a new treatment target for advanced prostate cancer. The discovery could potentially lead to the development of targeted therapies that selectively attack cancer cells while leaving healthy cells intact.
Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. The study provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer.
Researchers have found a new treatment for prostate cancer using gold nanoparticles produced from chemicals in tea leaves, reducing tumors by 80 percent and requiring doses thousands of times smaller than chemotherapy. The nanoparticles are attracted to tumor cells and destroy them efficiently.
A study published in Journal of Biological Chemistry found that prostate cancer cells lacking the protein SPDEF are unable to establish colonies at possible sites of metastasis, highlighting a potential biomarker for untreated cancers. Researchers hope to regulate SPDEF expression to prevent cancer cell metastasis.
Researchers at the University of Houston will pursue projects related to prostate cancer, diabetes, and obesity with funding from the NIH and DOD. The center's eight active NIH grants account for more than $18 million in research funding.
Researchers have discovered a novel mechanism for generating cancer-driving genes, bypassing chromosomal translocation. The SLC45A3-ELK4 fusion RNA promotes prostate cancer cell growth and disease progression in human samples.
Researchers found African-American survivors have unmet needs in dealing with fears of recurrence, while spouses report concerns about stress and anxiety. The study highlights the importance of culturally appropriate interventions, including improved communication and symptom management for better outcomes.
A new line of radioisotope therapy, Radium-223 chloride, has been shown to extend the lives of prostate cancer patients with advanced tumors that have spread to bone. The treatment has a short range of penetration and is usually well-tolerated, with serious side effects being rare.
A team of UC Davis investigators found that a p53 genetic mutation may initiate prostate cancer, differing from the current conventional wisdom. The study developed a mouse model with the mutation, which significantly increased the likelihood of developing prostate cancer.
A new medication, abiraterone acetate, has been shown to slow the spread of metastatic prostate cancer while maintaining quality of life in patients. The study involved 1,088 men and demonstrated improved survival and reduced need for chemotherapy and pain medications.
The CNRCS has awarded three students for their work on prostate cancer, including Jayantha Tennakoon, who aims to identify molecules that provoke cancer cell growth. Undergraduate Hannah Do is maintaining a drug library to isolate new therapeutic targets for advanced prostate cancer. Eylem Aydogdu became the first Ph.D. graduate at the...
A survey of primary care doctors found that many resist stopping routine PSA testing due to patient expectations and malpractice concerns. Researchers are working on a decision-making tool to help doctors make informed choices about prostate cancer screening.
The USPSTF recommends against PSA-based screening for all men regardless of age, citing significant harms associated with the test. The Task Force concludes that the benefits of screening do not outweigh the risks, which include unnecessary treatments and life-long adverse effects.
Researchers found that statin users had less prostate growth compared to non-users, regardless of whether they took dutasteride or a placebo. The effect was relatively small and tapered off after two years.
A study presented at the American Urological Association Annual Meeting found that early stage prostate cancer treatment can alleviate lower urinary tract symptoms (LUTS) in a subgroup of men. Radical prostatectomy surgery was shown to improve urinary function, while radiation therapy and brachytherapy had less favorable effects.
Researchers have identified a unique molecular subtype of prostate cancer associated with mutations in the SPOP gene, accounting for up to 15% of all cases. The study reveals that these mutations may lead to an accumulation of proteins driving cancer growth.
A new UCLA study finds that nerve-sparing surgical techniques and experienced surgeons can improve erectile function after prostate cancer surgery. Surgeons with at least 1,000 cases under their belt and those who actively seek improvement have better outcomes.
A phase II clinical trial found that abiraterone acetate, a hormone-depleting drug, can nearly eliminate or eliminate tumors in patients with aggressive cancers isolated to the prostate gland. The study showed promising results, encouraging further research into new treatments for high-risk prostate cancer.
Researchers will investigate Cu-64, a biomolecule that selectively seeks out a prostate tumor biomarker, to stage prostate cancers and detect recurrent disease accurately. The new technique involves PET scans and could significantly reduce the number of confirmation biopsies.
A new study found that patients undergoing radical prostatectomy surgery in accredited teaching hospitals with residency programs experienced fewer complications than those in non-teaching institutions. Those with private insurance also had better outcomes. The study suggests that specialized care and peer-review processes may contribu...
Research at Henry Ford Hospital found that higher hospital volume and surgeon volume both lead to better surgical results, but hospital volume matters more for older, sicker patients. The study analyzed data from 19,225 Medicare patients with prostate cancer who underwent radical prostatectomy between 1995 and 2005.
A recent study found racial disparities in the results of radical prostatectomy for African American patients compared to white patients. The researchers identified five areas where African Americans had poorer outcomes, including blood transfusions, complications during and after surgery, and prolonged hospital stays.
Researchers identify DNA methylation profiles as potential biomarkers for detecting prostate cancer months earlier than current methods. The discovery also predicts recurrence risk and identifies genes that can be targeted with new drugs.
A new technique has been reported in the American Journal of Pathology that uses genetic abnormalities to predict prostate cancer relapse. The study found that copy number variations (CNVs) in both cancerous and non-cancerous tissues can accurately forecast recurrence, allowing for more targeted treatment approaches.
Research suggests that PSA screening can reduce deaths from prostate cancer in younger, healthy men. The benefit of screening is particularly significant in men with risk factors such as black ancestry or positive family history. Screening may be discontinued for elderly men with multiple comorbidities and limited life expectancy.